Global Assistive Reproductive Technology Market
Global Assistive Reproductive Technology Market was valued at US$ 23.6 Bn in 2018 and is projected to exhibit a CAGR of 5.3% during the forecast period (2019–2027), as mentioned in a new report published by Coherent Market Insights.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/3041
During the forecast period, the global assistive reproductive technology market is projected to expand due to frequent product releases and approvals. Manufacturers are concentrating on releasing new models and expanding their ART offerings. Hamilton Thorne Ltd., a manufacturer of precision instruments, consumables, applications, and facilities, introduced TrakJector, a micromanipulator device that provides ART laboratories with special and intuitive control over quick and precise ICSI (intracytoplasmic sperm injection) and embryo biopsy procedures. Hamilton Thorne Ltd., a global distributor of assisted reproductive technology (ART), announced the extension of its product line for the ART market in North America on a direct distribution basis in October 2017. Gynemed Glass Micropipettes, Micromanipulation System, Hamilton Thorne DuraSlides, Halosperm DNA Fragmentation Kits, and others are among the items available. Merck KGaA, a science and technology firm, announced the introduction of QBOX IVF in July 2018, which streamlines data transfer between lab instruments and EMR providers. They also released the latest Geri Assess 2.0 in the same year and month, which allows for automated monitoring of main events in embryo and blastocyst development and increases embryo evaluation performance. These two devices are used in IVF and ART clinics.
Furthermore, at the 72nd American Society for Reproductive Medicine (ASRM) Scientific Congress in October 2016, EMD Serono, Merck KGaA’s biopharmaceutical company, announced the launch of the New Fertility Technologies Division.
The global assistive reproductive technology market is expected to expand in the near future due to rising prevalence and occurrence of infertility. The number of ART clinics has increased as the prevalence and incidence of infertility has increased. As per the National Centers for Chronic Disease Prevention and Health Promotion, there are 499 ART clinics in the U.S., with 464 clinics reporting details (related to ART procedures) to the CDC, which states that 464 clinics completed 231,936 ART cycles in the U.S. in 2015.
Browse 37 Market Data Tables, and 25 Figures spread through 170 Pages and in-depth TOC on Global Assistive Reproductive Technology Market, by Product Type (Consumables and Instruments); by Technology (IVF (In-vitro fertilization) (IVF with ICSI (Intracytoplasmic Sperm Injection) and IVF without ICSI (Intracytoplasmic Sperm Injection), AI-IUI (Artificial Insemination-Intrauterine Insemination), Frozen Embryo Replacement (FER) and Others), by Procedure (Fresh Nondonor, Egg/Embryo Banking, Fresh Donor, Frozen Nondonor, Frozen Donor, and Others), by End User (Hospital, Fertility Clinics, and IVF Center), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/3041
Strategic investments are being made by major market leaders in order to broaden their product range. Cooper Surgical Inc., purchased LifeGlobal Group and its affiliates in April 2018, a global manufacturer of in-vitro fertilisation (IVF) products. Cooper Surgical’s fertility media services are expected to be strengthened as a result of this purchase, as well as their fertility market. Cooper Surgical Inc. purchased The Pipette Company (TPC), an Adelaide, Australia-based producer and dealer of micropipettes for the ART market, in February 2016.
Due to the regular releases and approvals of assistive reproductive technology devices, the global assistive reproductive technology market is projected to develop at a CAGR of 5.3 percent during the forecast period (2019–2027).
Due to a rise in ART centres and growing public consciousness of ART, North America is forecast to hold a leading role in the global assistive reproductive technology market.
Due to rising infertility rates among people aged 35-40 and increased understanding of IVF procedures and ART technology, Asia Pacific and Europe are expected to be potential markets.
Major companies contributing in the global assistive reproductive technology market are Merck KGaA, Vitrolife AB, FUJIFILM Irvine Scientific, Inc., IVFtech ApS, Hamilton Thorne, Inc., CellCura ASA, Cooper Surgical Inc., Cook Medical LLC., Gonagen Medikal, INVO Bioscience, EMD Serono, Inc., and Nidacon International AB.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027